The effects of CCK-4 on plasma arginine-vasopressin and oxytocin levels in women with and without premenstrual dysphoric disorder

Author： Le Melleacute do J.M.   Bradwejn J.   Koszycki D.   Bellavance F.   Steinberg S.   Halbreich U.   Legrand J.-M.   Bichet D.G.  

Publisher： Elsevier

ISSN： 0924-977X

Source： European Neuropsychopharmacology, Vol.5, Iss.3, 1995-09, pp. : 266-266

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of Antidepressants on Quality of Life in Women with Premenstrual Dysphoric Disorder

By Freeman Ellen W.  

PharmacoEconomics, Vol. 23, Iss. 5, 2005-01 ,pp. : 433-444

Adis International

Access to resources Recommend Favorite

Premenstrual dysphoric disorder: is it simply PMS?

By Endicott J.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 259-259

Elsevier

Access to resources Recommend Favorite

Role of family history and 5-HTTLPR polymorphism in female seasonal affective disorder patients with and without premenstrual dysphoric disorder

By Praschak-Rieder N.   Willeit M.   Winkler D.   Neumeister A.   Hilger E.   Zill P.   Hornik K.   Stastny J.   Thierry N.   Ackenheil M.   Bondy B.   Kasper S.  

European Neuropsychopharmacology, Vol. 12, Iss. 2, 2002-04 ,pp. : 129-134

Elsevier

Access to resources Recommend Favorite

Duloxetine for premenstrual dysphoric disorder: a pilot study

By Mazza Marianna   Harnic Desiree   Catalano Valeria   Janiri Luigi   Bria Pietro  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 4, 2008-03 ,pp. : 517-521

Informa Healthcare

Access to resources Recommend Favorite

Luteal Phase Administration of Agents for the Treatment of Premenstrual Dysphoric Disorder

By Freeman E.W.  

CNS Drugs, Vol. 18, Iss. 7, 2004-01 ,pp. : 453-468

Adis International

Access to resources Recommend Favorite